

Appendix K: References

Master Web Resource list

Mr. Greg Banner (gregoryb@doh.state.ri.us) Emergency Manager for the Rhode Island Department of Health maintains a master list of web sites useful for medical emergency planning. The list is updated regularly and includes numerous CBRNE related sites. It is available as a WORD document and may be downloaded at: http://www.health.ri.gov/biot/web_sites.doc

Introduction / History of Biological Warfare and the Current Threat

1. Alibek K. Biohazard. Random House, New York. 1999.
2. Carus WS. Bioterrorism and Biocrimes: The Illicit Use of Biological Agents Since 1900. National Defense University, Center for Counterproliferation Research, Fredonia Books, 2002
3. CDC, 2003. Investigation of a ricin-containing envelope at a postal facility--South Carolina, 2003. MMWR 52:1129-31.
4. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM, 1997. Biological warfare. A historical perspective. JAMA. 278:412-7.
5. Fenn E. Pox Americana. Hill & Wang, 2002.
6. Harris SH. Factories of death. New York, NY. Routledge, 1994.
7. Mayor A. Greek Fire, Poison Arrows & Scorpion Bombs: Biological and Chemical Warfare in the Ancient World. The Overlook Press, New York, 2003.
8. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, et al. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 1994 266:1202-8.
9. Noah DL, Huebner KD, Darling RG, Waeckerle J, 2002. The history and threat of biological warfare and terrorism. Emerg Med Clin North Am 20:255-71.
10. Takahashi H, Keim P, Kaufmann AF, Keys C, et al., 2004. *Bacillus anthracis* bioterrorism Incident, Kameido, Tokyo, 1993. EID 10:117-20.

Distinguishing Between Natural and Intentional Disease Outbreaks

1. Biological Weapons Improved Response Program (BW IRP) Updated BW Response Decision Tree and BW Response Template, May 2001: http://hld.sbccom.army.mil/downloads/bwirp/bwirp_updated_decision_tree_report.pdf
2. Biological Weapons Improved Response Program (BW IRP) Response Decision Tree Workshop, April 1999: http://hld.sbccom.army.mil/downloads/bwirp/bwirp_decision_tree_report.pdf
3. NPDO/DoD Criminal and Epidemiological Investigation Report, January 2000: http://hld.sbccom.army.mil/downloads/bwirp/bwirp_npdo_dod_ceir.pdf
4. Ashford DA, Kaiser RM, Bales ME, Shutt K, Patrawalla A, McShan A, Tappero JW, Perkins BA, Dannenberg AL. Planning against biological terrorism: lessons from outbreak investigations. Emerg Infect Dis 2003 9:515-9.

5. Dembek ZF, Buckman RL, Fowler SK, Hadler JL. Missed sentinel case of naturally occurring pneumonic tularemia outbreak: lessons for detection of bioterrorism. *J Am Board Fam Pract* 2003;16:339-42.
6. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Etzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. *JAMA* 1997;278:399-411.
7. Grunow R, Finke EJ. A procedure for differentiating between the intentional release of biological warfare agents and natural outbreaks of disease: its use in analyzing the tularemia outbreak in Kosovo in 1999 and 2000. *Clin Microbiol Infect* 2002;8:510-21.
8. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh WJ, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL; National Anthrax Epidemiologic Investigation Team. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. *Emerg Infect Dis* 2002;8:1019-28.
9. Koss T, Carter EL, Grossman ME, Silvers DN, Rabinowitz AD, Singleton J Jr, Zaki SR, Paddock CD. Increased detection of rickettsialpox in a New York City hospital following the anthrax outbreak of 2001: use of immunohistochemistry for the rapid confirmation of cases in an era of bioterrorism. *Arch Dermatol* 2003;139:1545-52.
10. Noah DL, Sobel AL, Ostroff SM, Kildew JA. Biological warfare training: infectious disease outbreak differentiation criteria. *Mil Med* 1998;163:198-201.
11. Pavlin J. Epidemiology of bioterrorism. *Emerg Infect Dis* 1999;5:528-30.
12. Reintjes R, Dedushaj I, Gjini A, Jorgensen TR, Cotter B, Lieftucht A, D'Ancona F, Dennis DT, Kosoy MA, Mulliqi-Osmani G, Grunow R, Kalaveshi A, Gashi L, Humolli I. Tularemia outbreak investigation in Kosovo: case control and environmental studies. *Emerg Infect Dis* 2002;8:69-73.
13. Reissman DB, Steinberg EB, Magri JM, Jernigan DB. The anthrax epidemiologic tool kit: an instrument for public health preparedness. *Biosecur Bioterror* 2003;1:111-6.
14. Takahashi H, Keim P, Kaufmann AF, Keys C, Smith KL, Taniguchi K, Inouye S, Kurata T. *Bacillus anthracis* incident, Kameido, Tokyo, 1993. *Emerg Infect Dis* 2004;10:117-20. *Emerg Infect Dis* 2004;10:385.
15. Torok TJ, Tauxe RV, Wise RP, Livengood JR, Sokolow R, Mauvais S, Birkness KA, Skeels MR, Horan JM, Foster LR. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. *JAMA* 1997;278:389-95.
16. Treadwell TA, Koo D, Kuker K, Khan AS. Epidemiologic clues to bioterrorism. *Public Health Rep*. 2003 Mar-Apr;118(2):92-8.
17. Zelicoff AP. An Epidemiological Analysis of the 1971 Smallpox outbreak in Aralsk, Kazakhstan. *Crit Rev Microbiol* 29:97-108.

Medical Management

1. Cieslak TJ, Christopher GW, Eitzen EM. Bioterrorism alert for healthcare workers. In: Bioterrorism and Infectious Agents: A New Dilemma for the 21st Century, Fong IW, ed. Kluwer, New York NY [in press].
2. Cieslak TJ, Rowe JR, Kortepeter MG, Madsen JM, Newmark J, Christopher GW, Culpepper RC, Eitzen EM. A field-expedient algorithmic approach to the clinical management of chemical and biological casualties. *Milit Med* 2000;165:659-62.
3. Cieslak TJ, Henretig FM. Medical consequences of biological warfare: the ten commandments of management. *Milit Med* 2001;166[suppl 2]:11-12.
4. Henretig FM, Cieslak TJ, Kortepeter MG, Fleisher GR. Medical management of the suspected victim of bioterrorism: an algorithmic approach to the undifferentiated patient. *Emergency Medicine Clinics of North America* 2002;20:351-64.
5. Kortepeter M, Christopher G, Cieslak T, et al. Medical Management of Biological Casualties Handbook. 4th ed. Fort Detrick: United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 2001.

Anthrax

1. Cieslak TJ, Eitzen EE Jr. Clinical and Epidemiologic Principles of Anthrax. *Emerg Infect Dis* 1999 5:552-5.
2. Dewan PK, Fry AM, Laserson K, et al. Inhalational anthrax outbreak among postal workers, Washington, DC, 2001. *Emerg Infect Dis* 2002;8:1066-72.
3. Fact Sheet: Anthrax Information for Health Care Providers.
<http://www.bt.cdc.gov/agent/anthrax/anthrax-hcp-factsheet.pdf>
4. Fennelly KP, Davidow AL, Miller SL, Connell N, Ellner J. Airborne infection with *Bacillus anthracis*—from mills to mail. *Emerg Infect Dis* 2004 10:996-1001.
5. Follow-up of deaths among U.S. Postal Service workers potentially exposed to *Bacillus anthracis* - District of Columbia, 2001-2002. *MMWR* 2003 / 52(39):937-938.
6. Gursky E, Inglesby TV, O'Toole T. Anthrax 2001: observations on the medical and public health response. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science* 2003; 1:97-110.
7. Hsu VP, Lukacs SL, Handzel T, and colleagues. Opening a *Bacillus anthracis*-containing envelope, Capitol Hill, Washington, D.C.: the public health response. *Emerg Infect Dis* 2002 8:1039-43.
8. Inglesby TV, Henderson DA, John G. Bartlett JG, and colleagues; for the Working Group on Civilian Biodefense. Anthrax as a biological weapon. *JAMA* 1999 281:1735-1745.
9. Inglesby TV, O'Toole T, MD, MPH; Henderson, DA; for the Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. *JAMA* Vol. 287 No. 17, May 1, 2002.
10. Status of U.S. Department of Defense preliminary evaluation of the association of anthrax vaccination and congenital anomalies. *MMWR* 2002 51:127.
11. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the advisory committee on immunization practices. *MMWR* 2002 51:1024-1026.

Brucellosis

1. Brucellosis outbreak at a pork processing plant -- North Carolina, 1992. MMWR 1994 43:113-116.
2. Colmenero JD, Reguera JM, Martos F, et al., 1996. Complications associated with *Brucella melitensis* infection: a study of 530 cases. Medicine 75:195-211.
3. Harris NL, McNeely WF, Shepard J-A O, et al. Weekly clinicopathological exercises: case 22-2002. N Engl J Med 347:200-206.
4. McLean DR, Russell N, Khan MY, 1992. Neurobrucellosis: clinical and therapeutic features. Clin Infect Dis 15:582-590.
5. Nielsen K, Duncan JR, eds., 1990. Animal Brucellosis. CRC Press, LLC. Boca Raton, FL.
6. Solera J, Martinez-Alfaro E, and Espinosa A, 1997. Recognition and optimum treatment of brucellosis. Drugs 53:245-256.
7. Suspected brucellosis case prompts investigation of possible bioterrorism-related activity - New Hampshire and Massachusetts, 1999. MMWR 2000 49:509-512.
8. Young EJ, Corbel MJ, eds., 1989. Brucellosis: clinical and laboratory aspects. CRC Press, LLC. Boca Raton, FL.

Glanders / Melioidosis

1. Laboratory-acquired human glanders - Maryland, May 2000. MMWR 2000, 49(24);532-5.
2. Srinivasan A, Kraus CN, DeShazer D, Becker PM, Dick JD, Spacek L, Bartlet JG, Byrne WR, Thomas DL (2001): Glanders in a military research microbiologist. N Engl J Med 4:256-258.
3. Steele JH (1979): Glanders. In: Steele JH (ed). CRC Handbook Series in Zoonoses, Section A: Bacterial, Rickettsial and Mycotic Diseases, Vol. I. CRC Press, Boca Raton, FL, pp 339-362.
4. Verma RD (1981): Glanders in India with special reference to incidence and epidemiology. Indian Vet J 58:177-183.
5. Russell P, Eley SM, Ellis J, Green M, Bell DL, Kenny DJ, Titball RW (2000): Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother 45:813-818.
6. Robins GD (1906): A study of chronic glanders in man with report of a case: analysis of 156 cases collected from the literature. Stud R Victoria Hosp Montreal 1:1-98.
7. Neubauer, H, Meyer, H, Finke, EJ (1997): Human glanders. Revue Internationale Des Services De Sante Des Forces Armees 70:258-265.
8. Mendelson RW (1950): Glanders. U. S. Armed Forces Med J 7:781-784.
9. Howe C, Miller WR (1947): Human glanders: report of six cases. Ann Intern Med 1:93-115.
- Batmanov VP (1993): Treatment of experimental glanders with combinations of sulfazine or sulfamonomethoxine with trimethoprim. Antibiot Khimioter 38:18-22.
10. Currie BJ, and Susan P. Jacups. Intensity of rainfall and Severity of melioidosis, Australia. Vol. 9, No. 12 December 2003 page numbers??

11. Po-Ren Hsueh, Lee-Jene Teng, Li-Na Lee, Cheong-Ren Yu, Pan-Chyr Yang, Shen-Wu Ho, and Kwen-Tay Luh, Melioidosis: An emerging infection in Taiwan? *EID J* 7, No. 3. May–Jun 2001.
12. Wang YS, Wong CH, Kurup A. Cutaneous melioidosis and necrotizing fasciitis caused by *Burkholderia pseudomallei*. *JOURNAL??Vol.* 9, No. 11 November 2003.
13. Huffam S, Jacups SP, Kittler P, Currie BJ. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters. *Trop Med Int Health.* 2004 Jun;9:715-7.
14. O'Brien M, Freeman K, Lum G, Cheng AC, Jacups SP, Currie BJ. Further evaluation of a rapid diagnostic test for melioidosis in an area of endemicity. *J Clin Microbiol.* 2004 May;42:2239-40.
15. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. Outcomes of patients with melioidosis treated with meropenem. *Antimicrob Agents Chemother* 2004 May;48:1763-5.
16. Leelarasamee A. Recent development in melioidosis. *Curr Opin Infect Dis* 2004 Apr;17:131-6.
17. Warawa J, Woods DE. Melioidosis vaccines. *Expert Rev Vaccines* 2002 Dec;1:477-82.
18. Kosuwon W, Taimglang T, Sirichativapee W, Jeeravipoolvarn P. Melioidotic septic arthritis and its risk factors. *J Bone Joint Surg Am* 2003 Jun;85-A:1058-61.
19. White NJ. Melioidosis. *Lancet* 2003 May 17;361:1715-22.

Plague

1. "Facts About Pneumonic Plague" available online from the CDC: <http://www.bt.cdc.gov/agent/plague/factsheet.pdf>
2. "Frequently Asked Questions About Plague" available online from the CDC: <http://www.bt.cdc.gov/agent/plague/plaguefaq.pdf>
3. Boulanger LL, Ettestad P, Fogarty JD, Dennis DT, Romig D, Mertz G. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999. *Clin Infect Dis.* 2004 38:663-9..
4. Campbell GL, Dennis DT. Plague and other *Yersinia* infections. In: Kasper DL, et al; eds. *Harrison's Principles of Internal Medicine.* 14th ed. New York: McGraw Hill, 1998:975-83.
5. Centers for Disease Control and Prevention. Prevention of plague. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR,* 1996;45(RR-14):1-15.
6. Dennis DT and Gage JL. Plague. In: Armstrong D and Cohen J (eds.) *Infectious Diseases.* London: Mosby, Armstrong, and Cohen, 1999.
7. Dennis, DT, Gratz N, Poland JD, and Tikhomirov E. Plague manual: epidemiology, distribution, surveillance and control. Geneva: World Health Organization, 1999.
8. Fritz CL, Dennis DT, Tipple MA, Campbell GL, McCance CR, and Gubler DJ. Surveillance for pneumonic plague in the United States during an international emergency: a model for control of imported emerging diseases. *Emerg Infect Dis* 1996;2:30-36

9. Gage KL. Plague. In: Colliers L, Balows A, Sussman M, Hausles WJ, eds. Topley and Wilson's Microbiology and Microbiological Infections, vol 3. London: Edward Arnold Press, 1998:885-903.
10. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, et al. Plague as a biological weapon: medical and public health management. *JAMA* 2000; 283:2281-90.
11. Perry RD, Fetherston JD. *Yersinia pestis* -- etiologic agent of plague. *Clin Microbiol Rev*, 1997;10:35-66.
12. Poland JD, Barnes AM. Plague. In Steele J (ed): *Handbook of Zoonoses*. Boca Raton, FL:CRC Press, 1979:515-559.
13. Teh W-L, 1926. Treatise on Pneumonic Plague. League of Nations Original Report

Q Fever

1. Burnet FM, Freeman M, 1937. Experimental studies on the virus of "Q" fever. *Med J Australia* 1:299-305.
2. Drancourt M, Raoult D, Xeridat B, Milandre L, Nesri M and Dano P. Q fever meningoencephalitis in five patients. *Eur J Epidemiol* 1991;7:134-8.
3. Fenollar F, Fournier P, Carrieri M, Habib G, Messana T and Raoult D. Risks factors and prevention of Q fever endocarditis. *Clin Infect Dis* 2001;33: p312-6.
4. Levy PY, Drancourt M, Etienne J, et al. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. *Antimicrob Agents Chemother* 1991;35:533-7.
5. Marrie TJ, 1995. *Coxiella burnetti* (Q fever) pneumonia. *Clin Infect Dis* 21(Suppl 3):S253-S264.
6. Marrie TJ, ed., 1990. Q fever, Volume I: The disease. CRC Press, LLC. Boca Raton, FL.
7. Maurin M, Raoult D. Q fever. *Clin Microbiol Revs* 1999;12:518-53.
8. Q Fever - California, Georgia, Pennsylvania, and Tennessee, 2000—2001. *MMWR* 2002, 51(41):924-927.
9. Raoult D, Fenollar F and Stein A. Q fever during pregnancy: diagnosis, treatment, and follow-up. *Arch Intern Med* 2002;162:701-4
10. Raoult D, Stein A. Q fever during pregnancy--a risk for women, fetuses, and obstetricians. *N Engl J Med* 1994;330: p371.
11. Raoult D. Treatment of Q fever. *Antimicrob Agents Chemother* 1993;37: p1733-6.
12. Sampere M, Font B, Font J, et al., 2003. Q fever in adults: review of 66 clinical cases. *Eur J Clin Microbiol Infect Dis* 22:108-110.
13. Williams JC, Thompson HA, eds., 1991. Q fever, Volume II: The biology of *Coxiella burnetii*. CRC Press, LLC. Boca Raton, FL.

Tularemia

1. Dembek ZF, Buckman RL, Fowler SK, Hadler JH. Missed sentinel case of naturally occurring pneumonic tularemia outbreak: lessons for detection of bioterrorism. *J. Am Board Fam Prac* 2003; 16:339-342.
2. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, et al. Tularemia as a biological weapon: medical and public health management. *JAMA* 2001; 285:2763-73.

3. Evans ME, Gregory DW, Schaffner W, McGee ZA, 1985. Tularemia: A 30-year experience with 88 cases. *Medicine (Baltimore)* 64:251-269.
4. Foshay L, 1938. Effects of serum treatment in 600 cases of acute tularemia. *JAMA* 110:603.
5. Francis E, 1925. Tularemia. *JAMA* 84:1243-1250.
6. Grunow R. A procedure for differentiating between the intentional release of biological warfare agents and natural outbreaks of disease: its use in analyzing the tularemia outbreak in Kosovo in 1999 and 2000. *Clin Microbiol Infect* 2002 Aug;8:510-21.
7. Reintjes R, Dedushaj I, Gjini A, Rikke-Jorgensen T, Benvon Cotter, Alfons Lieftucht, Fortunato D'Ancona, David T. Dennis, Michael A. Kosoy, Gjyle Mulliqi-Osmani, Roland Grunow, Ariana Kalaveshi, Luljeta Gashi, and Isme Humolli. Tularemia outbreak investigation in Kosovo: case control and environmental studies. *EID* Vol 8;1, Jan 2002.
8. Simpson W, 1929. Tularemia: History, Pathology, Diagnosis and Treatment. Paul B. Hoeber, Inc. New York.
9. Teutsch SM, Martone WJ, Brink EW, et al. Pneumonic tularemia on Martha's Vineyard. *New Engl J Med* 1979; 301:826-828.
10. Tularemia—United States, 1990-2000. *MMWR* 2002 Mar 8;51(9):182-184.

Smallpox

1. Bray M, Buller M. Looking back at smallpox. *Clin Infect Dis* 2004;38:882-9.
2. Breman JG, Henderson DA. Diagnosis and management of smallpox. *N Engl J Med* 2002;346:1300-8.
3. CDC Smallpox Response Plan and Guidelines (version 3.0).
<http://www.bt.cdc.gov/agent/smallpox/response-plan/index.asp>
4. CDC. Secondary and tertiary transfer of vaccinia virus Among U.S. military personnel - United States and worldwide, 2002-2004. *MMWR* February 13, 2004 / 53;103-105.
5. DHHS/PHS. Supplemental Guidance for Planning and Implementing the National Smallpox Vaccination Program (NSVP). 22 Nov 2002.
6. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. *N Engl J Med* 1987;316:673-6.
7. DoD Smallpox Response Plan.
<http://www.smallpox.mil/resource/SMAplan/complete/SMAplan.pdf>
8. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. WHO 1988.
9. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon. Medical and public health management. *JAMA* 1999;281:2127-2137.
10. Human monkeypox-Kasai Oriental, Democratic Republic of Congo (Zaire), 1996-1997. *MMWR* 1997;46:301-71.
11. Kesson A, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. *Clin Infect Dis* 1997;25:911-4.
12. McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. *J Infect Dis* 1997;175:756-63.
13. Vaccinia (Smallpox) vaccine: recommendations of the ACIP. *MMWR* (1991), 40:RR-14 (Suppl).

Venezuelan Equine Encephalitis

1. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. Venezuelan equine encephalitis. *Annu Rev Entomol* 2004;49:141-74.
2. Rivas F, Diaz LA, Cardenas VM, et al. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995. *J Infect Dis* 1997;175:828-32.
3. Bowen GS, Calisher CH. Virological and serological studies of Venezuelan equine encephalomyelitis in humans. *J Clin Microbiol* 1976;4:22-7.
4. de la Monte S, Castro F, Bonilla NJ, Gaskin de Urdaneta A, Hutchins GM. The systemic pathology of Venezuelan equine encephalitis virus infection in humans. *Am J Trop Med Hyg* 1985;34:194-202.
5. Watts DM, Callahan J, Rossi C, et al. Venezuelan equine encephalitis febrile cases among humans in the Peruvian Amazon River region. *Am J Trop Med Hyg* 1998;58:35-40.
6. Reed DS, Lind CM, Sullivan LJ, Pratt WD, Parker MD. Aerosol infection of cynomolgus macaques with enzootic strains of venezuelan equine encephalitis viruses. *J Infect Dis* 2004;189:1013-7.
7. Bowen GS, Fashinell TR, Dean PB, Gregg MB. Clinical aspects of human Venezuelan equine encephalitis in Texas. *Bull Pan Am Health Organ* 1976;10:46-57.

Viral Hemorrhagic Fevers

1. Armstrong LR, Dembry LM, Rainey PM, Russi MB, Khan AS, Fischer SH, Edberg SC, Ksiazek TG, Rollin PE, Peters CJ. Management of a Sabia virus-infected patient in a US Hospital. *Infect Control Hosp Epidemiol* 1999 20:176-82.
2. Barry M, Russi M, Armstrong L, Geller D, Tesh R, Dembry L, Gonzalez JP, Khan AS, Peters CJ. Brief report: treatment of a laboratory acquired Sabia virus infection. *N Engl J Med* 1995 333:294-6.
3. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillbridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. *JAMA* 2002 May 8;287(18):2391-405.
4. Christopher GW, Eitzen EM Jr. Air evacuation under high-level biosafety containment: the aeromedical isolation team. *Emerg Infect Dis* 1999;241-246.
5. Fisher-Hoch SP, Price ME, Craven RB, et al. Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. *Lancet* 1985;2:1227-9.
6. Holmes GP, McCormick JB, Trock SC, et al. Lassa fever in the United States: investigation of a case and new guidelines for management. *N Engl J Med* 1990;323:1120-3.
7. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. *Lancet* 1990;335:502-5.
8. Management of patients with suspected viral hemorrhagic fever. *MMWR* 1988;37: S-3 (Suppl).

9. Peters CJ, LeDuc JW, Breman JG, Jahrling PB, Rodier G, Rollin, PE, van der Groen, G. Ebola: The virus and the disease. *J Infect Dis* 1999;179:Supplement 1
10. Peters CJ, Sanchez A, Rollin PE, Ksiazek TG, Murphy FA. Filoviridae: Marburg and Ebola viruses. pp 1161-76, Fields Virology (3d ed.), Fields BN, Knipe DM, Howley PM, et al (eds). Philadelphia: Lippincott-Raven; 1996.
11. Update: Filovirus infections among persons with occupational exposure to nonhuman primates. *MMWR* 1990;39:266-7.
12. Update: Management of patients with suspected viral hemorrhagic fever- United States. *MMWR* 1995;44:475-9.

Botulism

1. Angulo FJ, Getz J, Taylor JP, et al. A large outbreak of botulism: the hazardous baked potato. *J Infect Dis* 178: 172-7.
2. Arnon SS, Schecter R, Inglesby TV, Henderson DA, et al. Botulism toxin as a biological weapon: medical and public health management. *JAMA* 2001; 285:1059-70.
3. Botulism Case Definition: <http://www.bt.cdc.gov/Agent/Botulism/CaseDef.asp>
4. Botulism in the United States 1899 – 1996. A Handbook for epidemiologists, clinicians, and laboratory workers.
<http://www.cdc.gov/ncidod/dbmd/diseaseinfo/botulism.pdf>
5. Facts about Botulism. <http://www.bt.cdc.gov/agent/botulism/factsheet.pdf>
6. Foodborne botulism - Oklahoma, 1994. *MMWR* March 24, 1995 / Vol. 44 / No. 11
7. New telephone number to report botulism cases and request antitoxin. *MMWR* 2003 Aug 15;52(32);774.
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5232a8.htm>
8. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. *JAMA* 1997; 278: 433-5.
9. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: A clinical and epidemiologic review. *Ann Intern Med* 1998;129:221-8.
10. Wound botulism - California, 1995. *MMWR* December 8, 1995/Vol. 44/No. 48

Ricin

1. Case definition of Ricin or Abrin inhalation.
<http://www.bt.cdc.gov/agent/ricin/ricininhcasedef.asp>
2. Challoner KR, McCarron MM. Castor bean intoxication. *Ann Emerg Med* 1990;19:159-65.
3. Facts about Ricin: <http://www.bt.cdc.gov/agent/ricin/pdf/ricinfacts.pdf>
4. Investigation of a ricin-containing envelope at a postal facility --- South Carolina, 2003. *MMWR* November 21, 2003 / 52;1129-1131.
5. Olsnes S, Kozlov JV. Ricin. *Toxicon* 2001;39:1723-8.
6. Questions and Answers about Ricin.
<http://www.bt.cdc.gov/agent/ricin/pdf/ricinqa.pdf>

Staphylococcal Enterotoxin B

1. Coffman JD, Zhu J, Roach JM, Bavari S, Ulrich RG, Giardina SL. Production and purification of a recombinant Staphylococcal enterotoxin B vaccine candidate expressed in *Escherichia coli*. Protein Expr Purif 2002 Mar;24:302-12.
2. Morissette, C., J. Goulet, and G. Lamoureux. 1991. Rapid and sensitive sandwich enzyme-linked immunosorbent assay for detection of staphylococcal enterotoxin B in cheese. Appl Environ Microbiol 57:836-842.
3. Nedelkov, D., A. Rasooly, and R. W. Nelson. 2000. Multitoxin biosensor-mass spectrometry analysis: a new approach for rapid, real-time, sensitive analysis of staphylococcal toxins in food. Int J Food Microbiol 60:1-13.
4. Schotte, U., N. Langfeldt, A. H. Peruski, and H. Meyer. 2002. Detection of staphylococcal enterotoxin B (SEB) by enzyme-linked immunosorbent assay and by a rapid hand-held assay. Clin Lab 48:395-400.
5. Seprenyi G, Shibata T, Onody R, Kohsaka T. In staphylococcus enterotoxin B (SEB)-stimulated human PBMC, the LAK activity of non-T cells might have a major role in the mechanism of glomerular endothelial cells' injury. Immunobiology 1997 Jun;197:44-54.

Trichothecene Mycotoxins

1. Atroshi F, Rizzo A, Westermarck T, Ali-Vehmas T. Antioxidant nutrients and mycotoxins. Toxicology 2002 Nov 15;180:151-67.
2. Hamaki T, Kami M, Kishi A, Kusumi E, Kishi Y, Iwata H, Miyakoshi S, Ueyama J, Morinaga S, Taniguchi S, Ohara K, Muto Y. Vesicles as initial skin manifestation of disseminated fusariosis after non-myeloablative stem cell transplantation. Leuk Lymphoma. 2004 Mar;45:631-3.
3. Li FQ, Luo XY, Yoshizawa T. Mycotoxins (trichothecenes, zearalenone and fumonisins) in cereals associated with human red-mold intoxications stored since 1989 and 1991 in China. Nat Toxins 1999;7:93-7.
4. Luo Y, Yoshizawa T, Katayama T. Comparative study on the natural occurrence of Fusarium mycotoxins (trichothecenes and zearalenone) in corn and wheat from high- and low-risk areas for human esophageal cancer in China. Appl Environ Microbiol 1990 Dec;56:3723-6.
5. Rosen RT, Rosen JD, 1982. Presence of four *Fusarium* mycotoxins and synthetic material in 'yellow rain.' Evidence for the use of chemical weapons in Laos. Biomed Mass Spectrom 9:443-50.
6. Schollenberger M, Suchy S, Jara HT, Drochner W, Muller HM. A survey of *Fusarium* toxins in cereal-based foods marketed in an area of southwest Germany. Mycopathologia 1999;147:49-57.
7. Sudakin DL. Trichothecenes in the environment: relevance to human health. Toxicol Lett 2003 Jul 20;143:97-107.

Emerging Infections and Future Biological Weapons

1. Addressing Emerging Infectious Disease Threats: A Prevention Strategy for the United States. Atlanta, Georgia: U.S. Public Health Service, 1994.
2. Black, John L., Genome projects and gene therapy: gateways to next generation biological weapons, 2003. Milit Med, 168, 11:864-71.

3. Bridges CB, Harper SA, Fukuda K, et al., 2003. Prevention and control of influenza. recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003 Apr 25; 52(RR-8): 1-34; quiz CE1-4. Erratum in: MMWR 2003 Jun 6;52:526.
4. CDC. Addressing Emerging Infectious Disease Threats: A Prevention Strategy for the United States. Atlanta, Georgia: U.S. Public Health Service, 1994.
5. CDC. Revised US surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases - United States and worldwide, December 2003. MMWR 52:1202-1206.
6. CDC. Hendra Virus Disease and Nipah Virus Encephalitis. <http://cdc.gov/ncidod/dvrd/spb/mnpages/dispages/nipah.htm>
7. CDC. Avian Influenza in Humans. <http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm>
8. Cox NJ, Bender CA 1995. The molecular epidemiology of influenza viruses. Seminar in Virology 6:359-370.
9. Daly MJ. The Emerging Impact of Genomics on the Development of Biological Weapons. Clin Lab Med. 2001 Sep; 21(3):619-29.
10. Kagan E. Bioregulators as Instruments of Terror. Clin Lab Med. 2001 Sep; 21(3):607-18.
11. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N, Steinhauer DA, Daniels RS, Elliot A, Wiley DC, Skehel JJ. The structure and receptor-binding properties of the 1918 influenza hemagglutinin, Science 2004 303:1838-1842.
12. Harper SA, Fukuda K, Cox NJ, et al., 2003. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003 Sep 26; 52(RR-13): 1-8.
13. Revised US surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases – United States and worldwide, December 2003. MMWR 52:1202-1206.
14. Schrag SJ, Brooks JT, Van Beneden C., et al., 2004. SARS surveillance during emergency public health response, United States, March-July 2003. Emerg Infect Dis 10. <page numbers>

Detection

1. Espy MJ, Cockerill III FR, Meyer RF, Bowen MD, Poland GA, Hadfield TL, Smith TF. Detection of smallpox virus DNA by LightCycler PCR. J Clin Microbiol. 2002 40:1985-8. Erratum in: J Clin Microbiol 2002 40:4405.
2. Field PR, Mitchell JL, Santiago A, Dickeson DJ, Chan SW, Ho DW, Murphy AM, Cuzzubbo AJ, Devine PL. Comparison of a commercial enzyme-linked immunosorbent assay with immunofluorescence and complement fixation tests for detection of *Coxiella burnetii* (Q fever) immunoglobulin M. J Clin Microbiol 2000 38:1645-7.
3. Johnasson A, Berglund L, Eriksson U, Goransson I, Wollin R, Forsman M, Tarnvik A, Sjostedt A. Comparative analysis of PCR versus culture for diagnosis of ulceroglandular tularemia. J Clin Microbiol 2000 38:22-6.
4. Kulesh DA, Baker RO, Loveless BM, Norwood D, Zwiers SH, Mucker E, Hartmann C, Herrera R, Miller D, Christensen D, Wasieleski LP, Huggins J, Jahrling PB. Smallpox and pan-orthopox virus detection by real-time 3'-minor

- groove binder TaqMan assays on the Roche LightCycler and the Cepheid Smart Cycler platforms. *J Clin Microbiol* 2004;42:601-9.
5. Kraft AE, Kulesh DA. Applying molecular biological techniques to detecting biological agents. *Clin Lab Med* 2001;21:631-60.
 6. Ligler FS, Taitt CR, Shriver-Lake LC, Sapsford KE, Shubin Y, Golden JP. Array biosensor for detection of toxins. *Anal Bioanal Chem*. 2003;377:469-77.
 7. Maragos CM. Novel assays and sensor platforms for the detection of aflatoxins. *Adv Exp Med Biol* 2002;504:85-93.
 8. Probert WS, Schrader KN, Khuong NY, Bystrom SL, Graves MH. Real-time multiplex PCR assay for detection of *Brucella* spp., *B. abortus*, and *B. melitensis*. *J Clin Microbiol* 2004;42:1290-3.
 9. Rantakokko-Jalava K, Viljanen MK. Application of *Bacillus anthracis* PCR to simulated clinical samples. *Clin Microbiol Infect* 2003;10:1051-6.
 10. Tomaso H, Reisinger EC, Al Dahouk S, Frangoulidis D, Rakim A, Landt O, Neubauer H. Rapid detection of *Yersinia pestis* with multiplex real-time PCR assays using fluorescent hybridisation probes. *FEMS Immunol Med Microbiol* 2003;38:117-26.
 11. Uhl JR, Bell CA, Sloan LM, Espy MJ, Smith TF, Rosenblatt JE, Cockerill FR. Application of rapid-cycle real-time polymerase chain reaction for the detection of microbial pathogens: the Mayo-Roche Rapid Anthrax test. *Mayo Clin Proc* 2002;77:673-80.
 12. Weidmann M, Muhlberger E, Hufert FT. Rapid detection protocol for filoviruses. *J Clin Virol* 2004;30:94-9.

Personal Protection

1. 29 CFR 1910.120, 130, 132, 134 series,
http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=9696
2. FM 8-284 Treatment of Biological Warfare Agent Casualties, 17 July 2000
3. CDC. Biological and chemical terrorism: strategic plan for preparedness and response; recommendations of the CDC Strategic Planning Workgroup. *MMWR* 2000;49 (No. RR-4):1-14.
4. National Response Team Technical Assistance for Anthrax Response, Interim-Final Draft, Sep 2002, pp22-23,
http://wetp.org/Wetp/public/dwloads/HASL_334dnfile.PDF
5. JP 3-11 Joint Doctrine for Operations in Nuclear, Biological, and Chemical (NBC) Environments, 11 July 2000,
http://www.dtic.mil/doctrine/jel/new_pubs/jp3_11.pdf
6. USACHPPM Technical Guide 275 Personal Protective Equipment Guide for Military Medical Treatment Facility Personnel Handling Casualties from Weapons of Mass Destruction and Terrorism Events, Aug 2003
7. CDC Interim Recommendations for the Selection and Use of Protective Clothing and Respirators Against Biological Agents
<http://www.bt.cdc.gov/documentsapp/anthrax/protective/10242001Protective.pdf>
8. OSHA Guidance for Hospital-based First Receivers of Victims (draft) ****Final report due end of June.

Decontamination

1. FM 3-11.5 Multiservice Tactics, Techniques, and Procedures for Chemical, Biological, Radiological, and Nuclear (CBRN) Decontamination (draft)
2. Best Practices and Guidelines for Mass Personnel Decontamination, Technical Support Working Group (TSWG), 1st Ed., June 2003, http://www.tswg.gov/tswg/prods_pubs/prods_pubs.htm
3. FM 8-284 Treatment of Biological Warfare Agent Casualties, 17 July 2000
4. CDC. Biological and chemical terrorism: strategic plan for preparedness and response; recommendations of the CDC Strategic Planning Workgroup. MMWR 2000;49(No. RR-4):1–14.
5. National Response Team Technical Assistance for Anthrax Response, Interim-Final Draft, Sep 2002, pp53-59, http://wetp.org/Wetp/public/dwloads/HASL_334dnfile.PDF
6. JP 3-11 Joint Doctrine for Operations in Nuclear, Biological, and Chemical (NBC) Environments, 11 July 2000, http://www.dtic.mil/doctrine/jel/new_pubs/jp3_11.pdf
7. Lawson JR, Jarboe TL, Aid for Decontamination of Fire and Rescue Service Protective Clothing and Equipment After Chemical, Biological, and Radiological Exposures, NIST Special Publication 981, May 2002

Investigational New Drugs

Code of Federal Regulations, title 21 – Food and Drugs, Parts 11, 50, 54, 56, 312, 314

http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm#Introduction